Citations

Clear

479 citation(s) found for "Tobias, JS".

Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer
Oo, Htoo Zarni , Lohinai, Zoltán , Khazamipour, Nastaran, Lo, Joey, Kumar, Gunjan , Pihl, Jessica , Adomat, Hans , Nabavi, Noushin , Behmanesh, Hakhamanesh , Dagil, Robert , Choudhary, Swati , Gustavsson, Tobias , Clausen, Thomas Mandel , Esko, Jeffrey D. , Allen, Jeffrey W. , Tran, Nhan L. , Moldvay, Judit , Döme, Balázs , Salanti, Ali , Al-Nakouzi, Nader , Weiss, Glen J. , Daugaard, Mads , Dagil, Robert , Weiss, Glen J , Daugaard, Mads , Tran, Nhan L , Zhai, Beibei , Thompson, Michael A.

Mayo Clinic

Cancers | September 6, 2021 | Volume: 13 | Issue: 17 | Pages: 4489

10.3390/cancers13174489 | PMID 34503301 Get It

Broad-spectrum therapeutics in non-small cell lung cancer (NSCLC) are in demand. Most human solid tumors express proteoglycans modified with distinct oncofetal chondroitin sulfate (CS) chains that can be detected and targeted with recombinant VAR2CSA (rVAR2) proteins and rVAR2-derived therapeutics. Here, we investigated expression and targetability of oncofetal CS expression in human NSCLC. High oncofetal CS expression is associated with shorter disease-free survival and poor overall survival of clinically annotated stage I and II NSCLC patients (n = 493). Oncofetal CS qualifies as an independent prognosticator of NSCLC in males and smokers, and high oncofetal CS levels are more prevalent in EGFR/KRAS wild-type cases, as compared to mutation cases. NSCLC cell lines express oncofetal CS-modified proteoglycans that can be specifically detected and targeted by rVAR2 proteins in a CSA-dependent manner. Importantly, a novel VAR2-drug conjugate (VDC-MMAE) efficiently eliminates NSCLC cells in vitro and in vivo. In summary, oncofetal CS is a prognostic biomarker and an actionable glycosaminoglycan target in NSCLC.
Benzodiazepine administration patterns before escalation to second‐line medications in pediatric refractory convulsive status epilepticus
Sheehan, Theodore , Amengual‐Gual, Marta , Vasquez, Alejandra , Abend, Nicholas S. , Anderson, Anne E. , Arya, Ravindra , Aguilar, Cristina Barcia , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Gaínza‐Lein, Marina , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Jackson, Michele , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Reece, Latania, Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Shellhaas, Renée A. , Smith, Garnett , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Arya, Ravindra , Barcia Aguilar, Cristina , Farias-Moeller, Raquel , Gaillard, William D , Gaínza-Lein, Marina , Guerriero, Rejean M , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Shellhaas, Renée A , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Sheehan, Theodore , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | August 21, 2021 | Volume: 62 | Issue: 11 | Pages: 2766-2777

10.1111/epi.17043 | PMID 34418087 Get It

Abstract Objective This study was undertaken to evaluate benzodiazepine (BZD) administration patterns before transitioning to non‐BZD antiseizure medication (ASM) in pediatric patients with refractory convulsive status epilepticus (rSE). Methods This retrospective multicenter study in the United States and Canada used prospectively collected observational data from children admitted with rSE between 2011 and 2020. Outcome variables were the number of BZDs given before the first non‐BZD ASM, and the number of BZDs administered after 30 and 45 min from seizure onset and before escalating to non‐BZD ASM. Results We included 293 patients with a median (interquartile range) age of 3.8 (1.3–9.3) years. Thirty‐six percent received more than two BZDs before escalating, and the later the treatment initiation was after seizure onset, the less likely patients were to receive multiple BZD doses before transitioning (incidence rate ratio [IRR] = .998, 95% confidence interval [CI] = .997–.999 per minute, p = .01). Patients received BZDs beyond 30 and 45 min in 57.3% and 44.0% of cases, respectively. Patients with out‐of‐hospital seizure onset were more likely to receive more doses of BZDs beyond 30 min (IRR = 2.43, 95% CI = 1.73–3.46, p < .0001) and beyond 45 min (IRR = 3.75, 95% CI = 2.40–6.03, p < .0001) compared to patients with in‐hospital seizure onset. Intermittent SE was a risk factor for more BZDs administered beyond 45 min compared to continuous SE (IRR = 1.44, 95% CI = 1.01–2.06, p = .04). Forty‐seven percent of patients ( n = 94) with out‐of‐hospital onset did not receive treatment before hospital arrival. Among patients with out‐of‐hospital onset who received at least two BZDs before hospital arrival ( n = 54), 48.1% received additional BZDs at hospital arrival. Significance Failure to escalate from BZDs to non‐BZD ASMs occurs mainly in out‐of‐hospital rSE onset. Delays in the implementation of medical guidelines may be reduced by initiating treatment before hospital arrival and facilitating a transition to non‐BZD ASMs after two BZD doses during handoffs between prehospital and in‐hospital settings.
EEG Biomarkers of Repository Corticotropin Injection Treatment
Tanritanir, Ahmet, Vieluf, Solveig , Wang, Xiao‐Fan , Jafarpour, Saba, Jafarpour, Saba , Loddenkemper, Tobias , Vieluf, Solveig

Mayo Clinic

Journal of Clinical Neurophysiology | August 13, 2021 | Volume: 40 | Issue: 3 | Pages: 236-243

10.1097/wnp.0000000000000886 | PMID 34387275 Get It

Purpose: Hypsarrhythmia is one of the major diagnostic and treatment response criteria in infantile spasms (IS). The clinical and electrophysiological effect of repository corticotropin injection treatment on IS was evaluated using electrophysiological biomarkers. Methods: Consecutive infants (<24 months) treated with repository corticotropin injection for IS were included in this retrospective descriptive study. Inclusion criteria were (1) clinical IS diagnosis, (2) repository corticotropin injection treatment, and (3) consecutive EEG recordings before and after repository corticotropin injection treatment. Patients with tuberous sclerosis complex were excluded. Response to treatment was defined as freedom from IS for at least 7 consecutive days during the treatment and resolution of hypsarrhythmia. The authors defined “relapse” as the recurrence of seizures after an initial response. Electrophysiological biomarker assessment included evaluation of semiautomatic spike counting algorithm, delta power, and delta coherence calculation during non-REM sleep EEG. Results: One hundred fifty patients (83 males; 55%; median age of IS onset: 5.9 months) with complete data were included, including 101 responders (67%, 71 with sustained response, and 30 relapses). Fifty patients (33%) with complete EEG data also underwent advanced EEG analysis. Baseline delta coherence was higher in sustained responders than in nonresponders or patients who relapsed. Greater decreases in semiautomatic spike counting algorithm, delta power, and delta coherence were found in sustained responders compared with nonresponders or patients who relapsed. Conclusions: Repository corticotropin injection treatment was associated with a 67% response rate in patients with IS. Computational biomarkers beyond hypsarrhythmia may provide additional information during IS treatment, such as early determination of treatment response and outcome assessment.
Predictive modeling of spread in adult‐onset isolated dystonia: Key properties and effect of tremor inclusion
Wang, Meng , Morgante, Francesca , Adler, Charles H. , Bäumer, Tobias , Berardelli, Alfredo , Blumin, Joel H. , Borsche, Max , Brashear, Allison , Deik, Andres , Duque, Kevin R. , Feuerstein, Jeanne , Fox, Susan H. , LeDoux, Mark S. , Leegwater‐Kim, Julie, Mahajan, Abhimanyu , Ondo, William G. , Pantelyat, Alexander , Pirio‐Richardson, Sarah, Roze, Emmanuel , Saunders‐Pullman, Rachel , Suchowersky, Oksana , Truong, Daniel , Morgante, Francesca , Adler, C H , Berardelli, Alfredo , Borsche, Max , Mahajan, Abhimanyu , Martino, Davide , Pantelyat, Alex , Sajobi, Tolulope T. , Berman, Brian D. , Espay, Alberto J. , Ferrazzano, Gina , Frank, Samuel , Hallett, Mark , Jankovic, Joseph J. , Malaty, Irene A. , Vidailhet, Marie , Shukla, Aparna Wagle , Perlmutter, Joel S. , Jinnah, H. A.

Mayo Clinic

European Journal of Neurology | July 22, 2021 | Volume: 28 | Issue: 12 | Pages: 3999-4009

10.1111/ene.15031 | PMID 34296504 Get It

AbstractBackground and purposeSeveral clinical and demographic factors relate to anatomic spread of adult‐onset isolated dystonia, but a predictive model is still lacking. The aims of this study were: (i) to develop and validate a predictive model of anatomic spread of adult‐onset isolated dystonia; and (ii) to evaluate whether presence of tremor associated with dystonia influences model predictions of spread.MethodsAdult‐onset isolated dystonia participants with focal onset from the Dystonia Coalition Natural History Project database were included. We developed two prediction models, one with dystonia as sole disease manifestation (“dystonia‐only”) and one accepting dystonia OR tremor in any body part as disease manifestations (“dystonia OR tremor”). Demographic and clinical predictors were selected based on previous evidence, clinical plausibility of association with spread, or both. We used logistic regressions and evaluated model discrimination and calibration. Internal validation was carried out based on bootstrapping.ResultsBoth predictive models showed an area under the curve of 0.65 (95% confidence intervals 0.62–0.70 and 0.62–0.69, respectively) and good calibration after internal validation. In both models, onset of dystonia in body regions other than the neck, older age, depression and history of neck trauma were predictors of spread.ConclusionsThis predictive modeling of spread in adult‐onset isolated dystonia based on accessible predictors (demographic and clinical) can be easily implemented to inform individuals’ risk of spread. Because tremor did not influence prediction of spread, our results support the argument that tremor is a part of the dystonia syndrome, and not an independent or coincidental disorder.
Factors associated with long‐term outcomes in pediatric refractory status epilepticus
Gaínza‐Lein, Marina , Aguilar, Cristina Barcia , Piantino, Juan , Chapman, Kevin , Fernández, Iván Sánchez , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Brenton, J. Nicholas , Carpenter, Jessica L. , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , Huh, Linda , Kahoud, Robert J., McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Nayak, Anuranjita , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Reece, Latania, Riviello, James J. , Sannagowdara, Kumar , Sands, Tristan T. , Sheehan, Theodore , Tasker, Robert C. , Vasquez, Alejandra , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Zhang, Bo , Barcia Aguilar, Cristina , Sánchez Fernández, Iván , Arya, Ravindra , Farias-Moeller, Raquel , Gaillard, William D , Kahoud, Robert, Lai, Yi-Chen , Mikati, Mohamad A , Morgan, Lindsey A , Novotny, Edward J , Sands, Tristan T , Sheehan, Theodore , Loddenkemper, Tobias , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Appavu, Brian , Glauser, Tracy A. , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Epilepsia | July 12, 2021 | Volume: 62 | Issue: 9 | Pages: 2190-2204

10.1111/epi.16984 | PMID 34251039 Get It

AbstractObjectiveThis study was undertaken to describe long‐term clinical and developmental outcomes in pediatric refractory status epilepticus (RSE) and identify factors associated with new neurological deficits after RSE.MethodsWe performed retrospective analyses of prospectively collected observational data from June 2011 to March 2020 on pediatric patients with RSE. We analyzed clinical outcomes from at least 30 days after RSE and, in a subanalysis, we assessed developmental outcomes and evaluated risk factors in previously normally developed patients.ResultsFollow‐up data on outcomes were available in 276 patients (56.5% males). The median (interquartile range [IQR]) follow‐up duration was 1.6 (.9–2.7) years. The in‐hospital mortality rate was 4% (16/403 patients), and 15 (5.4%) patients had died after hospital discharge. One hundred sixty‐six (62.9%) patients had subsequent unprovoked seizures, and 44 (16.9%) patients had a repeated RSE episode. Among 116 patients with normal development before RSE, 42 of 107 (39.3%) patients with available data had new neurological deficits (cognitive, behavioral, or motor). Patients with new deficits had longer median (IQR) electroclinical RSE duration than patients without new deficits (10.3 [2.1–134.5] h vs. 4 [1.6–16] h, p = .011, adjusted odds ratio = 1.003, 95% confidence interval = 1.0008–1.0069, p = .027). The proportion of patients with an unfavorable functional outcome (Glasgow Outcome Scale‐Extended score ≥ 4) was 22 of 90 (24.4%), and they were more likely to have received a continuous infusion.SignificanceAbout one third of patients without prior epilepsy developed recurrent unprovoked seizures after the RSE episode. In previously normally developing patients, 39% presented with new deficits during follow‐up, with longer electroclinical RSE duration as a predictor.
Abstract 13996: Does Copeptin Provide Additional Risk Stratification in Chest Pain Patients With a Mild Troponin Elevation?
Mueller, Christian, Xavier-Neath, Sean, Christenson, Robert H. , McCord, Jim, Nowak, Richard M. , Vilke, Gary M. , Daniels, Lori B. , Apple, Fred S. , Cannon, Chad , Nagurney, John Tobias , Schreiber, Donald , Diercks, Deborah B. , Wu, Alan H.B. , Clopton, Paul , Jaffe, Allan S. , Peacock, Frank , Maisel, Alan S. , Daniels, Lori B , Marston, Nicholas , Shah, Kevin S , Hollander, Judd E. , deFilippi, Christopher R. , Hogan, Christopher , Limkakeng, Alexander T. , Anand, Inder S. , Jaffe, Allan S.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.13996 Get It

Introduction: Copeptin has demonstrated a role in early rule out for acute myocardial infarction in combination with a negative troponin. However, the value of copeptin in patients with a positive troponin is not established. Hypothesis: The addition of a baseline copeptin at chest pain presentation will improve risk stratification in patients with mild troponin elevation. Methods: The multi-center CHOPIN trial enrolled 2071 acute chest pain patients. All subjects with ST segment elevations were excluded from this analysis. Of the remaining patients, 124 had a mildly elevated troponin (defined by < 2x URL) and were included in the study cohort. Baseline cTnI and copeptin levels were drawn on presentation, and another cTnI at 2 hours. Copeptin ≤14 pmol/l and troponin deltas ≤10% from baseline were considered positive. Two independent blinded cardiologists adjudicated AMI diagnosis. The value of a baseline copeptin in this cohort was assessed using AMI incidence, odds ratio, sensitivity, and negative predictive value (NPV). Results: Of the 124 patients in the study cohort, 73 (59%) had an elevated copeptin and an associated AMI incidence of 25% (18 AMIs). The remaining 51 patients (41%) were copeptin negative and diagnosed with 3 AMIs, an incidence of 5.9% (p = 0.006, figure 1). A positive copeptin increased the likelihood of AMI diagnosis with an odds ratio of 5.3 (95% CI: 1.5-19.2). The sensitivity and NPV for AMI were 86% and 94%, both of which were higher than the delta troponin (table 1). When an initial copeptin was combined with the delta troponin the sensitivity and NPV for AMI improved to 100%. Conclusion: Use of copeptin in chest pain patients with mild troponin elevation provides further risk stratification. The combination of copeptin with a delta troponin may aid in earlier AMI rule out in this subset of patients. This approach could be especially relevant as the increasing use of high sensitivity troponin assays leads to greater rates of mild troponin elevations.
European Heart Journal quality standards
Alfonso, Fernándo , Carter, Rickey E. , Carter, Rickey E , Torp-Pedersen, Christian Tobias , Crea, Filippo

Mayo Clinic

European Heart Journal | June 27, 2021 | Volume: 42 | Issue: 28 | Pages: 2729-2736

10.1093/eurheartj/ehab324 | PMID 34289494 Get It

Abstract The aim of the European Heart Journal (EHJ) is to attract innovative, methodologically sound, and clinically relevant research manuscripts able to change clinical practice and/or substantially advance knowledge on cardiovascular diseases. As the reference journal in cardiovascular medicine, the EHJ is committed to publishing only the best cardiovascular science adhering to the highest ethical principles. EHJ uses highly rigorous peer-review, critical statistical review and the highest quality editorial process, to ensure the novelty, accuracy, quality, and relevance of all accepted manuscripts with the aim of inspiring the clinical practice of EHJ readers and reducing the global burden of cardiovascular diseases. This review article summarizes the quality standards pursued by the EHJ to fulfill its mission.
Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study
Vasquez, Alejandra , Farias‐Moeller, Raquel , Sánchez-Fernández, Iván, Amengual‐Gual, Marta , Anderson, Anne E. , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Abend, Nicholas S. , Arya, Ravindra , Glauser, Tracy A. , Guerriero, Rejean M , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Pediatric Critical Care Medicine | June 14, 2021 | Volume: 22 | Issue: 12 | Pages: e613-e625

10.1097/pcc.0000000000002786 | PMID 34120133 Get It

OBJECTIVES: To characterize the pediatric super-refractory status epilepticus population by describing treatment variability in super-refractory status epilepticus patients and comparing relevant clinical characteristics, including outcomes, between super-refractory status epilepticus, and nonsuper-refractory status epilepticus patients. DESIGN: Retrospective cohort study with prospectively collected data between June 2011 and January 2019. SETTING: Seventeen academic hospitals in the United States. PATIENTS: We included patients 1 month to 21 years old presenting with convulsive refractory status epilepticus. We defined super-refractory status epilepticus as continuous or intermittent seizures lasting greater than or equal to 24 hours following initiation of continuous infusion and divided the cohort into super-refractory status epilepticus and nonsuper-refractory status epilepticus groups. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We identified 281 patients (157 males) with a median age of 4.1 years (1.3–9.5 yr), including 31 super-refractory status epilepticus patients. Compared with nonsuper-refractory status epilepticus group, super-refractory status epilepticus patients had delayed initiation of first nonbenzodiazepine-antiseizure medication (149 min [55–491.5 min] vs 62 min [33.3–120.8 min]; p = 0.030) and of continuous infusion (495 min [177.5–1,255 min] vs 150 min [90–318.5 min]; p = 0.003); prolonged seizure duration (120 hr [58–368 hr] vs 3 hr [1.4–5.9 hr]; p < 0.001) and length of ICU stay (17 d [9.5–40 d] vs [1.8–8.8 d]; p < 0.001); more medical complications (18/31 [58.1%] vs 55/250 [22.2%] patients; p < 0.001); lower return to baseline function (7/31 [22.6%] vs 182/250 [73.4%] patients; p < 0.001); and higher mortality (4/31 [12.9%] vs 5/250 [2%]; p = 0.010). Within the super-refractory status epilepticus group, status epilepticus resolution was attained with a single continuous infusion in 15 of 31 patients (48.4%), two in 10 of 31 (32.3%), and three or more in six of 31 (19.4%). Most super-refractory status epilepticus patients (30/31, 96.8%) received midazolam as first choice. About 17 of 31 patients (54.8%) received additional treatments. CONCLUSIONS: Super-refractory status epilepticus patients had delayed initiation of nonbenzodiazepine antiseizure medication treatment, higher number of medical complications and mortality, and lower return to neurologic baseline than nonsuper-refractory status epilepticus patients, although these associations were not adjusted for potential confounders. Treatment approaches following the first continuous infusion were heterogeneous, reflecting limited information to guide clinical decision-making in super-refractory status epilepticus.
Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort)
Sculier, Claudine , Aguilar, Cristina Barcia , Gaspard, Nicolas , Gaínza‐Lein, Marina , Fernández, Iván Sánchez , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Burrows, Brian T., Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , Gorman, Mark , McDonough, Tiffani L. , Mikati, Mohamad A. , Nayak, Anuranjita , Peariso, Katrina , Riviello, James J. , Rusie, Allison, Sperberg, Katherine , Stredny, Coral M. , Tasker, Robert C. , Vasquez, Alejandra , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, pSERG, Barcia Aguilar, Cristina , Sánchez Fernández, Iván , Lai, Yi-Chen , Mikati, Mohamad A , Arya, Ravindra , Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaspard, Nicolas , Gaillard, William D , Glauser, Tracy A. , Lai, Yi‐Chen , Tchapyjnikov, Dmitry , Loddenkemper, Tobias , pSERG

Mayo Clinic

Epilepsia | June 7, 2021 | Volume: 62 | Issue: 7 | Pages: 1629-1642

10.1111/epi.16950 | PMID 34091885 Get It

AbstractObjectiveWe aimed to characterize the clinical profile and outcomes of new onset refractory status epilepticus (NORSE) in children, and investigated the relationship between fever onset and status epilepticus (SE).MethodsPatients with refractory SE (RSE) between June 1, 2011 and October 1, 2016 were prospectively enrolled in the pSERG (Pediatric Status Epilepticus Research Group) cohort. Cases meeting the definition of NORSE were classified as "NORSE of known etiology" or "NORSE of unknown etiology." Subgroup analysis of NORSE of unknown etiology was completed based on the presence and time of fever occurrence relative to RSE onset: fever at onset (≤24 h), previous fever (2 weeks–24 h), and without fever.ResultsOf 279 patients with RSE, 46 patients met the criteria for NORSE. The median age was 2.4 years, and 25 (54%) were female. Forty (87%) patients had NORSE of unknown etiology. Nineteen (48%) presented with fever at SE onset, 16 (40%) had a previous fever, and five (12%) had no fever. The patients with preceding fever had more prolonged SE and worse outcomes, and 25% recovered baseline neurological function. The patients with fever at onset were younger and had shorter SE episodes, and 89% recovered baseline function.SignificanceAmong pediatric patients with RSE, 16% met diagnostic criteria for NORSE, including the subcategory of febrile infection‐related epilepsy syndrome (FIRES). Pediatric NORSE cases may also overlap with refractory febrile SE (FSE). FIRES occurs more frequently in older children, the course is usually prolonged, and outcomes are worse, as compared to refractory FSE. Fever occurring more than 24 h before the onset of seizures differentiates a subgroup of NORSE patients with distinctive clinical characteristics and worse outcomes.